| Literature DB >> 30888498 |
M Veltcamp Helbach1, S E van Oostendorp2, T W A Koedam2, J J Knol3, H B A C Stockmann4, S J Oosterling4, R C L M Vuylsteke4, E J R de Graaf5, P G Doornebosch5, R Hompes6, H J Bonjer2, C Sietses7, J B Tuynman2.
Abstract
BACKGROUND: Transanal total mesorectal excision (TaTME) is a new complex technique with potential to improve the quality of surgical mesorectal excision for patients with mid and low rectal cancer. The procedure is technically challenging and has shown to be associated with a relative long learning curve which might hamper widespread adoption. Therefore, a national structured training pathway for TaTME has been set up in the Netherlands to allow safe implementation. The aim of this study was to monitor safety and efficacy of the training program with 12 centers.Entities:
Keywords: Proctoring; Rectal cancer; TAMIS; TaTME; Training
Year: 2019 PMID: 30888498 PMCID: PMC6946716 DOI: 10.1007/s00464-019-06750-w
Source DB: PubMed Journal: Surg Endosc ISSN: 0930-2794 Impact factor: 4.584
Patient characteristics
| Structured training program | |
|---|---|
| Sex | |
| Male | 91 (75.8) |
| Female | 29 (24.2) |
| BMI (mean) (± SD) | 26.9 (± 4.0) |
| Age (years) (mean) (± SD) | 65.4 (± 9,9) |
| History of abdominal surgery | |
| No | 91 (75.8) |
| Yes | 29 (24.2) |
| History of transanal surgery | |
| No | 115 (95.8) |
| Yes | 5 (4.2) |
| ASA | |
| I | 25 (21.4) |
| II | 75 (64.1) |
| III | 17 (14.5) |
| Missing data | 3 (2.5) |
| Tumor height (AV) (cm) (mean) (± SD) | 6.9 (± 3.1) |
| Tumor stage | |
| T1 | 6 (5.1) |
| T2 | 23 (19.5) |
| T3 | 87 (73.7) |
| T4 | 2 (1.7) |
| Missing data | 2 (1.7) |
| Mesorectal fascia involvement | |
| No | 97 (82.2) |
| Yes | 21 (17.8) |
| Missing data | 2 (1.7) |
| Preoperative therapy | |
| None | 43 (35.8) |
| RT | 41 (34.2) |
| CRT | 36 (30.0) |
Numbers in parentheses are percentages, unless mentioned otherwise
BMI body mass index (kg/m2), SD standard deviation, ASA American Society of Anesthesiologists, cm centimeters, AV anal verge, RT radiotherapy, CRT chemoradiotherapy
Operative details
| Structured training program | |
|---|---|
| Type of surgery | |
| LAR | 110 (91.7) |
| Intersphincteric | 10 (8.3) |
| Anastomosis | |
| No | 22 (18.3) |
| Yes | 98 (81.7) |
| Stoma type | |
| None | 20 (16.7) |
| Diverting ileostomy | 77 (64.1) |
| Colostomya | 23 (19.2) |
| Technique anastomosis | |
| Hand sewn | 5 (5.1) |
| Stapled | 93 (94.9) |
| Type anastomosis | |
| Side-to-end | 36 (36.7) |
| End-to-end | 62 (63.3) |
| Specimen removal | |
| Pfannenstiel | 68 (57.6) |
| Transanally | 31 (26.3) |
| Stoma site | 3 (2.5) |
| Laparotomy | 5 (4.2) |
| Small transverse incision | 11 (9.3) |
| Missing data | 2 (1.7) |
| Operative time (min) (mean) (± SD) | 293.0 (± 92.6) |
| Blood loss (ml) (median) (range) | 100.0 (0–4050) |
| Conversionb | 5 (4.2) |
| Intraoperative events | |
| Urethral injury | 0 (0.0) |
| Pelvic bleeding | 2 (1.7) |
| Rectal perforation | 1 (0.8) |
| Small bowel injury | 1 (0.8) |
| Ureter injury | 1 (0.8) |
| Technical problemsc | 1 (0.8) |
Numbers in parentheses are percentages, unless mentioned otherwise
LAR low anterior resection, SD standard deviation, min minutes, ml milliliters
aIncludes 1 in situ loop transversostomy
bIncludes 1 early conversion
cComplete unilateral dissection, unable to safely progress contralateral
Postoperative details
| Structured training program | |
|---|---|
| Hospital stay (days) (median) (range) | 7 (3–43) |
| Postoperative complications CD | |
| None | 66 (55.0) |
| Minor (CD I-II) | 31 (25.8) |
| Major (CD ≥ III) | 23 (19.2) |
| IIIa | 7 (30.4) |
| IIIb | 16 (69.6) |
| Anastomotic leakage < 30 daysa | 17 (17.3) |
| Anastomotic treatmenta | |
| Endosponge | 5 (5.1) |
| Temporary ileostomy | 4 (4.1) |
| Unintended colostomy | 4 (4.1) |
| Suture | 2 (2.0) |
| Drainage | 1 (1.0) |
| Novel anastomosis | 1 (1.0) |
| 30-day mortality | 0 (0.0) |
Numbers in parentheses are percentages, unless mentioned otherwise
CD Clavien–Dindo classification
aOnly patients selected with anastomosis (n = 98)
Pathology reports
| Structured training program | |
|---|---|
| Pathology stage | |
| pT0 | 9 (7.6) |
| pT1 | 16 (13.6) |
| pT2 | 32 (28.8) |
| pT3 | 59 (50.0) |
| n.a | 2 (1.7) |
| Quality of specimen (Quirke)a | |
| Complete | 107 (89.2) |
| Nearly complete | 13 (10.8) |
| Incomplete | 0 (0.0) |
| CRM involvement | 6 (5.0) |
| DRM involvementb | 0 (0.0) |
| Lymph nodes harvested (mean) (± SD) | 17.0 (± 7.2) |
| Lymph nodes positive (median) (range) | 0 (0–7) |
Numbers in parentheses are percentages unless mentioned otherwise
CRM circumferential resection margin, DRM distal resection margin, SD standard deviation
aFrom Quirke et al. [18]
b1 missing patient
Learning effect within structured training program
| Patients 1–5 (60) | Patients 5–10 (60) | ||
|---|---|---|---|
| Sex (male) | 45 (75.0) | 46 (76.7) | 0.831 |
| BMI (mean) (± SD) | 26.5 (± 3.5) | 27.3 (± 4.5) | 0.269 |
| Age (years) (mean) (± SD) | 64.9 (± 10,3) | 66.0 (± 9.5) | 0.540 |
| ASA | |||
| I | 15 (26.3) | 10 (16.7) | 0.017 |
| II | 39 (68.4) | 36 (60.0) | |
| III | 3 (5.3) | 14 (23.3) | |
| Tumor height (AV) (cm) (mean) (± SD) | 6.7 (3.1) | 7.1 (3.0) | 0.519 |
| Tumor stage | |||
| T1 | 3 (5.1) | 3 (5.1) | 1000* |
| T2 | 12 (20.3) | 11 (18.6) | |
| T3 | 43 (72.9) | 44 (74.6) | |
| T4 | 1 (1.7) | 1 (1.7) | |
| Mesorectal fascia involvement | |||
| No | 49 (83.1) | 48 (81.4) | 0.810 |
| Yes | 10 (16.9) | 11 (18.6) | |
| Preoperative therapy | |||
| None | 18 (30.0) | 25 (41.7) | 0.406 |
| RT | 22 (36.7) | 19 (31.6) | |
| CRT | 20 (33.3) | 16 (26.7) | |
| Type of surgery | |||
| LAR | 53 (88.3) | 57 (95.0) | 0.186 |
| Intersphincteric | 7 (11.7) | 3 (5.0) | |
| Operative time (min) (mean) (± SD) | 283.6 (± 80.1) | 302.5 (± 103.6) | 0.266 |
| Conversion | 1 (1.7) | 4 (6.8) | 0.207* |
| Intraoperative complications | 3 (5.0) | 3 (5.1) | 0.1000* |
| Hospital stay (days) (median) (range) | 8 (3–43) | 7 (3–25) | 0.521* |
| Postoperative complications CD | |||
| None | 31 (51.7) | 35 (58.3) | 0.750 |
| Minor (CD I-II) | 17 (28.3) | 14 (23.4) | |
| Major (CD ≥ III) | 12 (20.0) | 11 (18.3) | |
| Anastomotic leakage < 30 daysa | 9 (18.8) | 8 (16.0) | 0.719 |
| Quality of specimen (Quirke)b | |||
| Complete | 48 (80.0) | 59 (98.3) | 0.001 |
| Nearly complete | 12 (20.0) | 1 (1.7) | |
| Incomplete | 0 (0.0) | 0 (0.0) | |
| CRM involvement | 1 (1.7) | 5 (8.3) | 0.207* |
Numbers in parentheses are percentages, unless mentioned otherwise
BMI Body Mass Index (kg/m2), SD standard deviation, ASA American Society of Anesthesiologists, RT radiotherapy, CRT chemoradiotherapy, LAR low anterior resection, min minutes, CD Clavien–Dindo classification, CRM circumferential resection margin
*Fisher’s Exact Test or Fishers–Freeman–Halton Test or Mann–Whitney U Test
aOnly patients selected with anastomosis (n = 98)
bFrom Quirke et al. [18]
Structured training program compared to other studies
| Structured training program | High volume | TaTME registry | Lap TME trials | |
|---|---|---|---|---|
| Sex (male) | 75.8 | 67.4 | 67.8 | 65 |
| Age (years) (mean) | 65.4 | 63.8 | 63.7 | 64 |
| BMI (mean) | 26.9 | 26.1 | 26.3 | 26.1–27 |
| Neoadjuvant (c)RT | 64.2 | 73.0 | 56.1 | 61.9 |
| Tumor height (cm) (mean) (AV) | 6.9 | 6.5 | 4.0$ | NA |
| cT3 or cT4 | 75.4 | 69.3 | 69.0 | NA |
| Conversion | 4.2 | 2.7 | 5.6 | 13.0 |
| Anastomotic leakage | 17.3 | NA | 15.7 | 7.9 |
| pT3 or pT4 | 50.0 | 45.1 | 43.5 | NA |
| Quality of specimen (Quirke)d | ||||
| Complete | 89.2 | 89.7 | 85.8 | 87.0 |
| Nearly complete | 10.8 | 9.0 | 10.8 | 13.0 |
| Incomplete | 0 | 1.3 | 3.4 | 4.0 |
| Missing | 9.7 | 6.0 | ||
| CRM involvement | 5.0 | 4.5 | 4.1 | 8.0 |
| DRM involvement | 0.0 | NA | 0.7 | NA |
All numbers are percentages, unless mentioned otherwise
TaTME transanal total mesorectal excision, Lap TME laparoscopic total mesorectal excision, BMI body mass index (kg/m2), (c)RT (chemo)radiotherapy, cm centimeters, AV anal verge, CRM circumferential resection margin, DRM distal resection margin
*From Penna et al. [9]
aFrom Deijen et al. [2]
bFrom van Oostendorp et al. [8]
cMedian from anorectal junction
dFrom Quirke et al. [18]